Director/PDMR Shareholding
22 February 2024 11:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 20 February 2024, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Executive Director and Chief Executive Officer. The AZIP award was granted on 24 March 2016 and was subject to a four-year performance period followed by a four-year holding period before vesting. Application of the performance measures specified at the time of grant